---
title: "EMVision Medical Devices  De-Risks Rural Stroke Use Cases with Aeromedical Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287699831.md"
description: "EMVision Medical Devices has completed a feasibility study for its First Responder Brain Scanner, validating its use in rural stroke cases. The study showed strong usability and positive patient experiences during aeromedical transfers. The scan data quality was unaffected by flight conditions, supporting regulatory approval progression. EMVision received a $400,000 milestone payment to aid in device development and reported $18.4 million in cash reserves. The company faces challenges in further clinical trials and securing funding for commercialization."
datetime: "2026-05-27T01:31:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287699831.md)
  - [en](https://longbridge.com/en/news/287699831.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287699831.md)
generator: "portal-rs"
---

# EMVision Medical Devices  De-Risks Rural Stroke Use Cases with Aeromedical Study

EMVision Medical Devices has reported successful completion of a feasibility study for its First Responder Brain Scanner, de-risking rural stroke use cases and validating scan data quality in flight conditions.

EMVision's First Responder Brain Scanner demonstrated strong operator usability and favourable patient experience during a Royal Flying Doctor Service (RFDS) aeromedical study.

The study, conducted with the **RFDS**, Australian Stroke Alliance, and South Australian Ambulance Service, saw **17 adult participants** enrolled across **15 transfers** at **12 airstrips**.

Flight nurses rated operator usability favourably across device preparation, patient set-up, and scanner operation.

Patient experience was also positive, with **92%** feeling calm during the scan and **100%** comfortable seeing the scanner used on a family member.

**Pathway to Regulatory Approval De-Risked**

Importantly, scan data quality remained as expected and was not materially impacted by flight conditions, even on transfers spanning **125km** to **371km** from **Adelaide Airport**.

The median scan time was **5 minutes 7 seconds**, which included a **3-minute** built-in redundant scan sequence, and the company expects production-equivalent devices to reduce this duration.

These findings support progression to production-equivalent commercial units for subsequent data collection and substantial equivalence testing, crucial steps for regulatory clearance.

EMVision is not only focused on aeromedical applications but is also preparing for additional pre-hospital studies beyond this setting.

This includes concluding the Mobile Stroke Unit (MSU) **Stage 1** and preparing for a standard road ambulance study, expanding the evidence base for its devices across various emergency environments.

**Continued Funding Support**

The company confirmed receipt of a **$400,000** non-dilutive milestone payment under the Australian Stroke Alliance project.

This payment provides further funding to support the progression of the First Responder device towards production-equivalent units for regulatory testing.

EMVision has consistently secured non-dilutive funding to advance its projects, recently receiving confirmation of a **$1.17 million** non-dilutive instalment under the Industry Growth Program in **May 2026**.

As at **31 March 2026**, EMVision reported holding **$18.4 million** in cash reserves, further bolstered by these recent grant receipts.

**Outlook and Risks**

The successful aeromedical study is a significant de-risking event for EMVision's First Responder device, validating its use in challenging environments and supporting its regulatory pathway.

However, ongoing challenges include executing further clinical trials, particularly the complexity of acute ischaemia detection within the emu Pivotal Trial, transitioning to production, and securing continued funding through milestone achievement.

The company remains dependent on successful development progress to translate R&D into commercialisation, and future grant instalments are contingent on meeting agreed milestones.

### Related Stocks

- [EMV.AU](https://longbridge.com/en/quote/EMV.AU.md)

## Related News & Research

- [EMVision Medical Devices Prepares Study to Support Remote Use of emu Bedside Brain Scanner](https://longbridge.com/en/news/297852214.md)
- [EMVision Making Strong Progress with emu and First Responder Brain Scanners](https://longbridge.com/en/news/292699934.md)
- [Q'Apel Medical Announces U.S. Launch of the Lynx™ Aspiration Catheter System](https://longbridge.com/en/news/298470392.md)
- [Boeing's new 777X is finally expected to fly passengers next year. Here are the 5 coolest cabin features.](https://longbridge.com/en/news/299088168.md)
- [EMVision Secures Nature-Portfolio Validation for AI Stroke Scanner](https://longbridge.com/en/news/292548185.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**